“Efficacy of Empagliflozin as Add-on Therapy in Patients with Uncontrolled Type 2 Diabetes Mellitus” (2023) TAJ: Journal of Teachers Association, 36(1), pp. 89–95. doi:10.3329/taj.v36i1.68304.